A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn’s Disease

• DOI: 10.2147/jir.s314912
• Publication Date: 2021-06-23T21:34:43Z
• Authors: Yueying Chen; Hanyang Li; Jing Feng; Shiteng Suo; Qi Feng; Jun Shen
• Keywords: Nomogram; Lasso

The prediction of the loss response (LOR) to infliximab (IFX) is crucial for optimizing treatment strategies and shifting biologics. However, a secondary LOR difficult predict by endoscopy due intestinal stricture, perforation, fistulas. This study aimed develop validate radiomic nomogram IFX in patients with Crohn's disease (CD).A total 186 biologic-naive diagnosed CD between September 2016 June 2019 were enrolled. Secondary was determined during week 54. Computed tomography enterography (CTE) texture analysis (TA) features extracted from lesions analyzed using LIFEx software. Feature selection performed least absolute shrinkage operator (LASSO) ten-fold cross validation. A constructed multivariable logistic regression, internal validation approached validation.Predictors contained radiomics included three first-order five second-order signatures. model presented significant discrimination (AUC, 0.880; 95% CI, 0.816-0.944) high calibration (mean error = 0.028). Decision curve (DCA) indicated that provided clinical net benefit. Ten-fold assessed stability an AUC 0.817 accuracy 0.819.This novel provides predictive tool assess disease. will help physicians decide when switch therapy.